Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9506
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McNamee, Nicholas | - |
dc.contributor.author | Harvey, Catriona | - |
dc.contributor.author | Gray, Lauren | - |
dc.contributor.author | Khoo, T. | - |
dc.contributor.author | Lingam, L. | - |
dc.contributor.author | Zhang, B. | - |
dc.contributor.author | Nindra, U. | - |
dc.contributor.author | Yip, P. Y. | - |
dc.contributor.author | Pal, A. | - |
dc.contributor.author | Clay, T. | - |
dc.contributor.author | Arulananda, S. | - |
dc.contributor.author | Itchins, M. | - |
dc.contributor.author | Pavlakis, N. | - |
dc.contributor.author | Kao, S. | - |
dc.contributor.author | Bowyer, S. | - |
dc.contributor.author | Chin, V. | - |
dc.contributor.author | Warburton, L. | - |
dc.contributor.author | Pires da Silva, Ines | - |
dc.contributor.author | John, T. | - |
dc.contributor.author | Solomon, B. | - |
dc.contributor.author | Alexander, M. | - |
dc.contributor.author | Nagrial, Adnan M. | - |
dc.date.accessioned | 2024-04-26T04:08:07Z | - |
dc.date.available | 2024-04-26T04:08:07Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Journal of Thoracic Oncology 19(4):636-642, 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9506 | - |
dc.description.abstract | BACKGROUND: Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-year overall survival of 10%. First-line immunotherapy with ipilimumab and nivolumab is now a standard of care for unresectable pleural mesothelioma following the CheckMate 743 trial, with supportive data from the later line single-arm MAPS2 trial. RIOMeso evaluates survival and toxicity of this regimen in real-world practice. METHODS: Demographic and clinicopathologic data of Australian patients treated with ipilimumab and nivolumab in first- and subsequent-line settings for pleural mesothelioma were collected retrospectively. Survival was reported using the Kaplan-Meier method and compared between subgroups with the log-rank test. Toxicity was investigator assessed using Common Terminology Criteria for Adverse Events version 5.0. RESULTS: A total of 119 patients were identified from 11 centers. The median age was 72 years, 83% were male, 92% had Eastern Cooperative Oncology Group less than or equal to 1, 50% were past or current smokers, and 78% had known asbestos exposure. In addition, 50% were epithelioid, 19% sarcomatoid, 14% biphasic, and 17% unavailable. Ipilimumab and nivolumab were used first line in 75% of patients. Median overall survival (mOS) was 14.5 months (95% confidence interval [CI]: 13.0-not reached [NR]) for the entire cohort. For patients treated first line, mOS was 14.5 months (95% CI: 12.5-NR) and in second- or later-line patients was 15.4 months (95% CI: 11.2-NR). There was no statistically significant difference in mOS for epithelioid patients compared with nonepithelioid (19.1 mo [95% CI: 15.4-NR] versus 13.0 mo [95% CI: 9.7-NR], respectively, p = 0.064). Furthermore, 24% of the patients had a Common Terminology Criteria for Adverse Events grade greater than or equal to 3 adverse events, including three treatment-related deaths. Colitis was the most frequent adverse event. CONCLUSIONS: Combination immunotherapy in real-world practice has poorer survival outcomes and seems more toxic compared with clinical trial data. This is the first detailed report of real-world survival and toxicity outcomes using ipilimumab and nivolumab treatment of pleural mesothelioma. | - |
dc.subject | Oncology | - |
dc.title | Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1016/j.jtho.2023.11.014 | - |
dc.subject.keywords | immunotherapy | - |
dc.subject.keywords | lung neoplasms | - |
dc.subject.keywords | mesothelioma | - |
dc.subject.keywords | pleura neoplasms | - |
dc.subject.keywords | asbestos | - |
dc.subject.keywords | ipilimumab | - |
dc.subject.keywords | nivolumab | - |
dc.identifier.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.department | Oncology | - |
dc.contributor.wslhd | McNamee, Nicholas | - |
dc.contributor.wslhd | Harvey, Catriona | - |
dc.contributor.wslhd | Gray, Lauren | - |
dc.contributor.wslhd | Pires da Silva, Ines | - |
dc.contributor.wslhd | Nagrial, Adnan M. | - |
dc.type.studyortrial | Clinical Trial | - |
dc.type.studyortrial | Controlled Study | - |
dc.type.studyortrial | Major Clinical Study | - |
dc.type.studyortrial | Retrospective Study | - |
dc.identifier.pmid | 38036250 | - |
dc.identifier.affiliation | The Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Garvan Institute of Medical Research, Sydney, Australia | - |
dc.identifier.affiliation | Sir Charles Gairdner Hospital, Perth, Australia | - |
dc.identifier.affiliation | Fiona Stanley Hospital, Perth, Australia | - |
dc.identifier.affiliation | Chris O'Brien Lifehouse, Sydney, Australia | - |
dc.identifier.affiliation | Liverpool Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Campbelltown Hospital, Sydney, Australia | - |
dc.identifier.affiliation | St. John of God Subiaco Hospital, Perth, Australia | - |
dc.identifier.affiliation | Edith Cowan University, Perth, Australia | - |
dc.identifier.affiliation | Monash Health, Melbourne, Australia | - |
dc.identifier.affiliation | Monash University, Melbourne, Australia | - |
dc.identifier.affiliation | Royal North Shore Hospital, Sydney, Australia | - |
dc.identifier.affiliation | University of Sydney, Sydney, Australia | - |
dc.identifier.affiliation | University of Western Australia, Perth, Australia | - |
dc.identifier.affiliation | University of New South Wales, Sydney, Australia | - |
dc.identifier.affiliation | Blacktown Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Australia | - |
dc.identifier.affiliation | University of Melbourne, Melbourne, Australia | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.